A Phase 3 interventional study of Ferric Carboxymaltose (FCM) and Ferrous Sulfate tablets in Postpartum Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2018-02-20.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.
Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 16th largest by enrollment, is the only one that started in 2006, is one of 23 in phase 3, and was the 3rd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:
Biocruces Bizkaia Health Research Institute · Sites in Spain
Ages 18+
Children's Hospital of Orange County
Ages 1–18
Helsinki University Central Hospital
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 24 · Phase 4 23
First in 2005; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 291 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 156 across the 54 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
19 studies in Anemia by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 19 studies in Anemia by Daiichi Sankyo, this one is the 8th largest by enrollment, is one of 2 that started in 2006, is one of 15 in phase 3, and was the 9th registered.
Daiichi Sankyo’s Anemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing ferric carboxymaltose in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIT45 compared to the current standard of care in postpartum patients.
This is an open label Phase III randomized active control study of postpartum patients with anemia. Patients will be randomized to either active control or the investigational agent and followed for up to 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
Drug: Ferric Carboxymaltose (FCM)
325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
Drug: Ferrous Sulfate tablets
Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL
Time frame: anytime between baseline and end of study or time to intervention
Reported Adverse Events
Time frame: anytime between baseline and end of study or time to intervention
Hospitals and medical clinics
| Milestone | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets |
|---|---|---|
| Started | 142 | 147 |
| Completed | 138 | 144 |
| Not completed | 4 | 3 |
| participants | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets |
|---|---|---|
| Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL | 127 | 98 |
Results for this outcome have not been posted.
Collected over 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose (FCM) | — | 4/142 (2.8%) | 9/142 (6.3%) |
| Ferrous Sulfate Tablets | — | 4/147 (2.7%) | 29/147 (19.7%) |
| Event | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets |
|---|---|---|
| EndometritisInfections and infestations | 0/142 | 2/147 |
| Pelvic abscessInfections and infestations | 0/142 | 2/147 |
| Pulmonary edemaRespiratory, thoracic and mediastinal disorders | 1/142 | 0/147 |
| Mitral valve prolapseCardiac disorders | 1/142 | 0/147 |
| HemorrhoidsGastrointestinal disorders | 1/142 | 0/147 |
| Cholecystitis acuteHepatobiliary disorders | 1/142 | 0/147 |
| PyelonephritisInfections and infestations | 1/142 | 0/147 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/142 | 1/147 |
| Event | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets |
|---|---|---|
| ConstipationGastrointestinal disorders | 2/142 | 18/147 |
| HeadacheNervous system disorders | 7/142 | 11/147 |
| Age, Categorical(Participants) | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| <=18 years | 14 | 7 | 21 |
| Between 18 and 65 years | 128 | 140 | 268 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| Mean | 26.43 ± 6.02 | 26.49 ± 5.55 | 26.45 ± 5.86 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| Female | 142 | 147 | 289 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ferric Carboxymaltose (FCM) | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| United States | 142 | 147 | 289 |
The record gives a start of May 2006, a primary completion of Dec 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose